OGT Focuses on Small NGS Cancer Panels for Clinical Research; Will Launch CE-IVD NIPT Array | GenomeWeb

NEW YORK (GenomeWeb) – Oxford Gene Technologies plans to develop a suite of narrowly targeted, disease-specific next-generation sequencing panels for the translational market in cancer and inherited disease, and also is working on an array-based test for noninvasive prenatal screening, company officials told GenomeWeb.

Last week, the Oxfordshire, UK-based molecular genetics firm launched an ovarian cancer panel and a library prep kit that Executive VP of Research and Development John Anson said would be the first of a number of NGS-based panels.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.